Cell Response and Regulation

CRR Membership Directory

cell response and regulation research programCell Response and Regulation (CRR) program conducts basic research on the fundamental cellular mechanisms that are deregulated in cancer cells. This discovery science provides new insight into cancer pathways and potential biomarkers.

The CRR program brings together scientists with shared research interests in three main thematic areas:

  • Mechanisms underlying cell turnover, including control of cell division, checkpoints, and cell death and their dysregulation in cancer in order to identify and characterize cancer targets.
  • Aberrant signaling in cancer and mechanisms of drug resistance, including signaling molecules and pathways relevant to drug resistance and cancer treatment.
  • Mechanisms and pathways mediating cell adhesion, motility, and metastasis, including developing an understanding of how cancer cells acquire the capability to reach distant sites and grow in those environments, which is critical for eventual therapeutic or preventative targeting.

CRR Program Newsletters

CRR 2014 Summer Newsletter

Previous newsletters are available upon request.
Please email kiera.powers@hci.utah.edu.

Program achievements include an improved understanding of the machinery that executes cell division, elucidation of signaling pathways involved in epithelial homeostasis and migration, and identification of a new biomarker for breast cancer, a critical mediator of drug resistance in myeloma, and factors that drive brain tumor and melanoma metastasis. A major asset of the CRR Program is the development of robust high-fidelity preclinical models of cancer. Basic CRR Program discoveries are leading to early phase clinical trials in breast cancer and melanoma and have impacted a chemoprevention trial in colon cancer.

The CRR Program is co-led by Douglas Grossman, MD, PhD, and Katharine Ullman, PhD, and draws its members from many academic units on campus, providing a forum for interdepartmental communication among individuals who share a common interest in understanding the cellular basis of cancer. The CRR Program stimulates scientific exchange and promotes cancer-focused transdisciplinary research by capitalizing on opportunities to link the diverse expertise in techniques and model systems in synergistic projects. This extends across Cancer Center Programs and is further promoted by the interface with disease focus groups.

The Cell Response and Regulation Program received $9.8 million in total research support from the National Institutes of Health, the American Cancer Society, the National Science Foundation, and other funding agencies in 2013, with 34% coming from the National Cancer Institute. Cancer-focused articles published between 2009-2013 total 212, of which 37% are inter-programmatic and 18% are intra-programmatic publications.

Douglas Grossman, MD, PhD
Co-Leader

Katharine S. Ullman, PhD
Co-Leader

doug grossman katherine ullman

HCI, Room 5262
801-581-4682
801-585-7477 FAX                                    

HCI, Room 5345
801-585-7123

CRR Membership Directory 

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Name E-mail Research Interests Website
Riccardo Baron, PhD e-mail Molecular origins of anticancer drug resistance, application of computational chemistry to drug development
Mary Beckerle, PhD e-mail Cell adhesion, cell migration, Ewing sarcoma website
Rachel Factor, MD e-mail
Breast cancer pathology
website
Adam Frost, MD, PhD e-mail
Mechanisms of cellular division and membrane trafficking
Daniel Fults, MD e-mail
Defective signaling in medulloblastoma and metastasis
Douglas Grossman, MD, PhD e-mail Apoptotic mechanisms underlying skin cancer development, with a focus on the apoptosis and cell cycle regulator, Survivin; oxidative stress in melanoma website
Sheri Holmen, PhD e-mail Identifying and validating novel molecular targets for cancer therapy website
Dean Li, MD, PhD e-mail Signaling in angiogenesis; targeting angiogenesis in cancer
Carol Lim, PhD e-mail Targeting apoptotic mechanisms in cancer cells
Philip Moos, PhD e-mail Redox dysregulation in cancer, selenoprotein function in cancer
Charles L. Murtaugh, PhD e-mail Pancreatic development and cancer
Thomas O'Hare, PhD e-mail
Target discovery and inhibitor development for chronic leukemia,
chemoresistance
website
Trudy Oliver, PhD e-mail Mouse models of lung cancer; chemotherapeutic resistance; p53 regulation website
Jody Rosenblatt, PhD e-mail
Mechanisms and regulation of cell death and division, novel mechanisms forinitiating tumor cell metastasis
website
Matthew Sigman, PhD e-mail
Synthesis and biological evaluation of novel small molecule platforms for cancer therapeutics
Gerald Spangrude, PhD e-mail
Stem cell biology in hematopoiesis and hematologic cancers
Diana Stafforini, PhD e-mail
Role of inflammation in colon and prostate cancer
website
Rodney Stewart, MPhil, PhD e-mail
Cell survival and migration during embryogenesis neural crest-derived cancers
website
Wesley Sundquist, PhD e-mail Cytokinesis and membrane trafficking website
Matthew Topham, MD e-mail
Lipid signaling in colon and lung cancer
website
Katharine Ullman, PhD e-mail Cell division, biomarkers and tumor suppressors in breast cancer website
Matthew VanBrocklin, PhD e-mail
Identifying novel molecular therapeutic targets in lung cancer and melanoma, chemoresistance
website
Alana Welm, PhD e-mail Tumor inflammation and breast cancer website
Bryan Welm, PhD e-mail Breast cancer stem cells, cancer drug screening website
Matthew Williams, PhD e-mail
Cellular and molecular signals regulating differentiation and cell fate
decisions of activated T cells infiltrating tumors
Guy Zimmerman, MD e-mail Cell adhesion and inflammation, thrombosis in cancer

Top